← All Kymera Therapeutics, INC filings

Kymera Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KYMR
Kymera Therapeutics, INC
10-K: Kymera Therapeutics Advances Pipeline, Secures Funding
Kymera Therapeutics reports significant progress in its clinical pipeline, including positive Phase 1b results for KT-621 in Atopic Dermatitis, new collaborations, and substantial capital raises, despite continued operating losses.
NASDAQ
KYMR
Kymera Therapeutics, INC
10-K: Kymera Therapeutics Reports 2024 Results, Highlights Clinical Progress and Financial Position
Kymera Therapeutics' 2024 10-K filing highlights clinical advancements in immunology programs and a strong financial position to support operations into mid-2027.
NASDAQ
KYMR
Kymera Therapeutics, INC
10-K: Kymera Therapeutics Reports 2023 Financial Results and Provides Pipeline Update
Kymera Therapeutics, a biopharmaceutical company, released its 2023 annual report, highlighting its progress in targeted protein degradation therapies and ongoing clinical trials.